Gastroenterology & Endoscopy (Jan 2024)

Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis

  • Alyaa Khaled Madeeh,
  • Hossam Khaled Farouk,
  • Mohamed Mohamed Belal,
  • Sara Ramadan,
  • Batool Emad Al-Masri,
  • Mohamed Samier,
  • Salama Ahmed Gadallah,
  • Naseba Khapoli,
  • Abdulqadir J. Nashwan,
  • Yossef Hassan AbdelQadir

Journal volume & issue
Vol. 2, no. 1
pp. 25 – 37

Abstract

Read online

Aim: This study aims to investigate the efficacy of nab-paclitaxel mono-chemotherapy as a second-line treatment for previously treated adenocarcinoma patients. Methods: We conducted a systematic review and meta-analysis of prospective single-arm clinical studies that tested nab-paclitaxel monotherapy for treating gastric carcinoma. The review was conducted in accordance with PRISMA. Results: We included 6 studies with a total of 271 patients. The pooled analysis of response rate, overall survival, and progression-free survival were 0.21 (95% CI: [0.16,0.28]), 11.65 (95% CI: [10.56, 12.75]), and 2.983 (95% CI: [2.625, 3.342]), respectively. There was no statistically significant difference between the doses regarding response rate and progression-free survival. However, the overall survival of the 150 ​mg/m2 dose was statistically significantly higher than the 260 ​mg/m2 dose. The treatment was associated with manageable toxicity profiles. Conclusion: Nab-paclitaxel mono-chemotherapy is an effective treatment option for previously treated and recurrent gastric cancer with a manageable toxicity profile. Future studies should aim to compare Nab-paclitaxel to other agents in direct head-to-head comparison.

Keywords